natgillin/translations-raw huggingface dataset:
Glivec er indiceret til behandling af voksne og børn med nydiagnosticeret Philadelphia-kromosom (bcr-abl) positiv (Ph+) kronisk myeloid leukæmi (CML), for hvilke knoglemarvstransplantation ikke anses for førstevalgsbehandling. voksne og børn med Ph+ CML i kronisk fase efter manglende effekt af alfa- interferonbehandling, eller i accelereret fase eller blastkrise. voksne og børn med nydiagnosticeret Philadelphia-kromosom-positiv akut lymfoblastær leukæmi (Ph+ ALL) integreret med kemoterapi. voksne patienter med Ph+ ALL med tilbagefald eller refraktær sygdom som monoterapi. voksne patienter med myelodysplastisk syndrom/myeloproliferative sygdomme (MDS/MPD) som er forbundet med platelet-derived growth factor receptor-omlejring (PDGFR-omlejring). voksne patienter med refraktært hypereosiniphil syndrom (HES) og/eller kronisk eosinofil leukæmi (CEL) med FIP1L1-PDGFR-omlejring.
Glivec is indicated for the treatment of adult and paediatric patients with newly diagnosed Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL) integrated with chemotherapy. adult patients with relapsed or refractory Ph+ ALL as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (HES) and/or chronic eosinophilic leukaemia (CEL) with FIP1L1-PDGFR rearrangement.
Glivec er indiceret til behandling af voksne patienter med Kit (CD 117) positiv, inoperable og/eller metastaserende maligne gastrointestinale bindevævstumorer (GIST). adjuverende behandling af voksne patienter, som har signifikant risiko for tilbagefald efter resektion af Kit (CD117)-positiv GIST.
Glivec is indicated for the treatment of adult patients with Kit (CD 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (GIST). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of Kit (CD117)-positive GIST.
Glivec hæmmer væksten af disse blodlegemer i en vis undergruppe af disse sygdomme.
Glivec inhibits the growth of these cells in a certain subtype of these diseases.
Glivec kan føre til, at din krop kan begynde at ophobe væske (svære ødemer).
Glivec may cause your body to retain water (severe fluid retention).
Glivec kan øge plasmakoncentrationen af andre CYP3A4- metaboliserede lægemidler (for eksempel triazol-benzodiazepiner, dihydropyridin- calciumantagonister, visse HMG-CoA reduktasehæmmere, såsom statiner osv.).
Glivec may increase plasma concentration of other CYP3A4 metabolised drugs (e.g. triazolo-benzodiazepines, dihydropyridine calcium channel blockers, certain HMG-CoA reductase inhibitors, i.e. statins, etc.).
Glivec vs. placebo
Glivec vs placebo
Glivec-behandling i 36 måneder forlængede signifikant RFS sammenlignet med 12 måneders Glivec- behandling (samlet hazard ratio (HR) = 0,46 [0,32-0,65], p<0,0001) (Tabel 8, Figur 1).
Thirty-six (36) months of Glivec treatment significantly prolonged RFS compared to 12 months of Glivec treatment (with overall Hazard Ratio (HR) = 0.46 [0.32, 0.65], p<0.0001) (Table 8, Figure 1).
Glivecs effekt er baseret på generelle hæmatologiske og cytogene responsrater og progressionsfri overlevelse.
The effectiveness of Glivec is based on overall haematological and cytogenetic response rates and progression-free survival.
Glivecs farmakokinetik er evalueret i dosisintervallet: 25–1.000 mg.
The pharmacokinetics of Glivec have been evaluated over a dosage range of 25 to 1,000 mg.
Glivectablet indeholder 400 mg imatinibmesilat.
Each tablet of Glivec contains 400 mg imatinib (as mesilate).
Global succes i MITT-populationen: primære og sekundære endemål
Global success in the MITT population: primary and secondary endpoints
Glomerulo nefritis
Glomerulonephritis
Glomerulo-
Haematuria
Glomerulo- nefritis, forhøjet blodkreatinin
Glomerulonephritis, blood creatinine increased
Glomerulo- nefritis, øget blodkreatinin
Glomerulonephritis, blood creatinine increased
Glomerulone fritis
Glomerulonephritis
Glomerulonefriti s
Glomerulonephri tis
Glomerulonefriti s
Glomerulonephritis
Glomerulonefritis
Epistaxis
Glomerulonefritis, verhoging van het bloedcreatinine
Glomerulonephritis, blood creatinine increased
Glomerulær filtrations- hastighed
Glomerular filtration rate Dose Frequency
glomerulær filtrationshastighed (CrCL)
glomerular filtration rate (CrCL,)
GLP-1 er en fysiologisk regulator af appetit og fødeindtagelse, men den eksakte virkningsmekanisme er ikke fuldstændigt klarlagt.
GLP­1 is a physiological regulator of appetite and food intake, but the exact mechanism of action is not entirely clear.
GLP-1-receptoren er mål for det native GLP-1, et endogent inkretinhormon, der potentierer glucoseafhængig insulinsekretion fra de pankreatiske betaceller.
The GLP­1 receptor is the target for native GLP­1, an endogenous incretin hormone that potentiates glucose­dependent insulin secretion from the pancreatic beta cells.
Glubrava
Competact
Glubrava 15 mg/850 mg filmovertrukne tabletter
Competact 15 mg/850 mg film-coated tablets
Glubrava 15 mg/850 mg filmovertrukne tabletter
Glubrava 15 mg/850 mg film-coated tablets
Glubrava 15 mg/850 mg filmovertrukne tabletter Pioglitazon/Metforminhydrochlorid
Competact 15 mg/850 mg film-coated tablets pioglitazone/metformin hydrochloride
Glubrava 15 mg/850 mg filmovertrukne tabletter Pioglitazon/Metforminhydrochlorid
Glubrava 15 mg/850 mg film-coated tablets Pioglitazone/Metformin hydrochloride
Glubrava 15 mg/850 mg tabletter
Competact 15 mg/850 mg
Glubrava 15 mg/850 mg tabletter
Glubrava 15 mg/850 mg tablets
Glubrava 15 mg/850 mg tabletter Pioglitazon/Metforminhydrochlorid
Competact 15 mg/850 mg tablets pioglitazone/metformin hydrochloride
Glubrava 15 mg/850 mg tabletter Pioglitazon/Metforminhydrochlorid
Glubrava 15 mg/850 mg tablets Pioglitazone/Metformin hydrochloride
Glubrava bør seponeres, hvis der opstår en forværring i kardiel status.
Competact should be discontinued if any deterioration in cardiac status occurs.
Glubrava er indiceret som andetvalgsbehandling af type 2-diabetes mellitus hos voksne patienter, særligt hos overvægtige patienter, som ikke kan opnå tilstrækkelig glykæmisk kontrol ved deres maksimalt tolererede dosis af oral metformin alene.
Competact is indicated as second line treatment of type 2 diabetes mellitus adult patients, particularly overweight patients, who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone.
Glubrava er kontraindiceret hos patienter med:
Competact is contraindicated in patients with:
Glubrava er kontraindiceret hos patienter med:
Glubrava is contraindicated in patients with:
Glubrava indeholder pioglitazon og metformin, som er lægemidler mod diabetes, som anvendes til at kontrollere blodsukkerniveauet.
Competact contains pioglitazone and metformin.
Glubrava kombinerer to antidiabetiske stoffer med komplementære virkningsmekanismer til forbedring af den glykæmiske kontrol hos patienter med type 2-diabetes: pioglitazon, der hører til thiazolidinedionerne og metforminhydrochlorid, der hører til biguaniderne.
Competact combines two antihyperglycaemic active substances with complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes mellitus: pioglitazone, a member of the thiazolidinedione class and metformin hydrochloride, a member of the biguanide class.
Glubrava kombinerer to antidiabetiske stoffer med komplementære virkningsmekanismer til forbedring af den glykæmiske kontrol hos patienter med type 2-diabetes: pioglitazon, der hører til thiazolidinedionerne og metforminhydrochlorid, der hører til biguaniderne.
Glubrava combines two antihyperglycaemic active substances with complementary mechanisms of action to improve glycaemic control in patients with type 2 diabetes: pioglitazone, a member of the thiazolidinedione class and metformin hydrochloride, a member of the biguanide class.
Glubrava må ikke anvendes hos patienter med nyresvigt eller nedsat nyrefunktion (kreatininclearance
Glubrava should not be used in patients with renal failure or renal dysfunction (creatinine clearance
Glubrava må ikke anvendes til kvinder i den fertile alder, som ikke anvender sikker kontraception.
Competact is not recommended in women of childbearing potential not using contraception.
Glubrava påvirker ikke eller kun i ubetydelig grad evnen til at føre motorkøretøj og betjene maskiner.
Competact has no or negligible influence on the ability to drive and use machines.
Glubrava-tabletter er hvide til offwhite, aflange, konvekse, filmovertrukne tabletter (tabletter) mærket med ‘15 / 850’ på den ene side og ‘4833M’ på den anden side.
Glubrava tablets are white to off white, oblong, convex, film-coated tablets (tablets) embossed ‘15 / 850’ on one face and ‘4833M’ on the other.
Glubrava-tabletter er hvide til offwhite, aflange, konvekse, filmovertrukne tabletter (tabletter) mærket med ‘15 / 850’ på den ene side og ‘4833M’ på den anden side.
The film-coated tablets (tablets) are white to off white, oblong, convex, embossed ‘15 / 850’ on one face and ‘4833M’ on the other.
Glubravas sikkerhed og virkning hos børn og unge under 18 år er ikke klarlagt.
The safety and efficacy of Competact in children and adolescents under 18 years of age have not been established.
glucagon (bugspytkirtelhormon, der anvendes til behandling af alvorlig hypoglykæmi),
glucagon (pancreas hormone used to treat severe hypoglycaemia),
glucagon (bugspytkirtelhormon, der anvendes til behandling af kritisk lavt blodsukker (hypoglykæmi),
glucagon (pancreas hormone used to treat severe hypoglycaemia),
glucagon (bugspytkirtelhormon, der anvendes til behandling af kritisk lavt blodsukker (hypoglykæmi),
glucagon(pancreas hormone used to treat severe hypoglycaemia),
glucagon (bugspytkirtelhormon, der anvendes til behandling af kritisk lavt blodsukker (svær hypoglykæmi),
glucagon (pancreas hormone used to treat severe hypoglycaemia),
Glucagon - til behandling af meget lavt blodsukker.
Glucagon – for very low blood sugar.
Glucokortikoider (givet systemisk og lokalt), beta-2-agonister og diuretika har en selvstændig hyperglykæmisk virkning.
Glucocorticoids (given by systemic and local routes) beta-2-agonists, and diuretics have intrinsic hyperglycaemic activity.
Glucose 50 mg/ml (5 %) injektionsvæske, opløsning
Dextrose 50 mg/ml (5%) solution for injection
Glucose 50 mg/ml (5 %) injektionsvæske, opløsning
Glucose 50 mg/ml (5 %) solution for injection
glucose 50 mg/ml (5%) infusionsvæske natriumchlorid 4,5 mg/l (0,45%) og glucose 50 mg/ml (5%) injektions-/infusionsvæske
glucose 50 mg/ml (5%) solution for infusion sodium chloride 4.5 mg/ml (0.45%) and glucose 50 mg/ml (5%) solution for injection/infusion
Glucose 50 mg/ml (5%) infusionsvæske, opløsning, kan også anvendes.
Glucose 50 mg/mL (5%) solution for infusion may also be used.
glucose 50 mg/ml (5%) injektionsvæske.
50 mg/mL (5%) glucose solution for injection.
Glucose 50 mg/ml (5%) til infusionsvæske, opløsning, kan også anvendes.
Glucose 50 mg/mL (5%) solution for infusion may also be used.
Glucose, 5 % injektionsvæske
Dextrose 5 % injection
Glucose, 50 mg/ml (5 %) injektionsvæske, opløsning
Dextrose 50 mg-ml (5%) solution for injection
Glucose, 50 mg/ml (5 %) injektionsvæske, opløsning
Dextrose 50 mg/ml (5%) solution for injection
Glucose-6-phosphatdehydrogenasemangel
Glucose-6-phosphate dehydrogensae deficiency
glucosei urinen
glucose urine present
Glucoseinfusionsrateprofil, udjævnet, steady state - Middelprofil 0-24 timer - IDeg 100 enheder/ml 0,6 enheder/kg - Studie 1987
Figure 1 Glucose infusion rate profile, smoothed, steady state - Mean profile 0-24 hours - IDeg 100 units/mL 0.6 units/kg - Trial 1987
Glucoseinfusionsrateprofiler, udjævnet, steady state - Middelprofiler 0-24 timer - IDeg 100 enheder/ml 0,6 enheder/kg - Studie 1987
Figure 1 Glucose infusion rate profile, smoothed, steady state - Mean profile 0-24 hours - IDeg 100 units/mL 0.6 units/kg - Trial 1987
glucoseinfusionsvæske 50 mg/ml (5%) eller natriumchlorid 4,5 mg/ml (0,45%) og glucose 50 mg/ml (5%) injektions-/infusionsvæske
glucose 50 mg/ml (5%) solution for infusion; or sodium chloride 4.5 mg/ml (0.45%) and glucose 50 mg/ml (5%) solution for injection/infusion.
glucoseinfusionsvæske 50 mg/ml (5%) eller natriumchlorid 4,5 mg/ml (0,45%) og glucose 50 mg/ml (5%) injektions-/infusionsvæske
glucose 50 mg/ml (5%) solution for infusion; sodium chloride 4.5 mg/ml (0.45%) and glucose 50 mg/ml (5%) solution for injection/infusion; or
glucoseinfusionsvæske 50 mg/ml (5%) natriumchlorid 4,5 mg/l (0,45%) og glucose 50 mg/ml (5%) injektions-/infusionsvæske
glucose 50 mg/ml (5%) solution for infusion sodium chloride 4.5 mg/ml (0.45%) and glucose 50 mg/ml (5%) solution for injection/infusion
glucoseinfusionsvæske 50 mg/ml (5%) natriumchlorid 4,5 mg/l (0,45%) og glucose 50 mg/ml (5%) injektions-/infusionsvæske eller
glucose 50 mg/ml (5%) solution for infusion; sodium chloride 4.5 mg/ml (0.45%) and glucose 50 mg/ml (5%) solution for injection/infusion; or
glucoseinfusionsvæske 50 mg/ml (5%) natriumchlorid 4,5 mg/ml (0,45%) og glucose 50 mg/ml (5%) injektions-/infusionsvæske eller
glucose 50 mg/ml (5%) solution for infusion; or sodium chloride 4.5 mg/ml (0.45%) and glucose 50 mg/ml (5%) solution for injection/infusion.
glucoseinfusionsvæske 50 mg/ml (5%) natriumchlorid 4,5 mg/ml (0,45%) og glucose 50 mg/ml (5%) injektions-/infusionsvæske eller
glucose 50 mg/ml (5%) solution for infusion; sodium chloride 4.5 mg/ml (0.45%) and glucose 50 mg/ml (5%) solution for injection/infusion; or
Glucoseintole- rans
Glucose intolerance;
Glucosemetabolisme
Glucose metabolism disorders
Glucosemonohydrat Povidone
Glucose monohydrate Povidone
glucoseniveauer 4
levels4
glucoseniveauer 4
occasionally associated
Glucoseniveauerne i blod og urin skal monitoreres i løbet af behandlingen med Oncaspar, da de kan være forhøjede.
Blood and urine glucose levels should be monitored during treatment with Oncaspar as they may rise.
Glucoseopløsning skal også gives intravenøst, hvis patienten ikke responderer på glucagon inden for 10–15 minutter.
Glucose must also be given intravenously, if the patient does not respond to glucagon within 10 to 15 minutes.
Glucoseudsvingene (AUC 0-6 timer) var 641 mg.time.dl-1 for insulin glulisin og 801 mg.time.dl-1 for regular human insulin.
The glucose excursion (AUC 0-6h) was 641 mg.h.dl-1 for insulin glulisine and 801 mg.h.dl-1 for regular human insulin.
Glucoseudsvingene (AUC 0-6 timer) var 641 mg.time.dl-1 for insulin glulisin og 801 mg.time.dl-1 for regular human insulin.
The glucose excursion (AUC0-6h) was 641 mg.h.dl-1 for insulin glulisine and 801 mg.h.dl-1 for regular human insulin.
glucosuri
glycosuria
Glucosuria Øget appetit
Glucosuria Increased appetite
Glukokokortikoidinduceret osteoporose:
Glucocorticoid-induced osteoporosis
Glukokortikoider (antiinflammatoriske lægemidler, der dæmper dit immunsystem), da anvendelse af glukokortikoider sammen med asparaginase kan øge dannelsen af blodpropper (trombose).
Glucocorticoids (anti-inflammation medicines that dampen down your immune system) since the simultaneous use of glucocorticoids and asparaginase may increase the formation of blood clots (thrombosis).
glukokortikoider (f.eks. beclometason, prednisolon), som er steroide lægemidler, der anvendes til behandling af inflammation ved tilstande såsom svær astma og arthritis
glucocorticoids (e.g. beclometasone, prednisolone) steroid medicines used to treat inflammation in conditions such as severe asthma, arthritis
Glukokortikoider (givet systemisk og lokalt), beta-2-agonister og diuretika har en selvstændig hyperglykæmisk virkning.
Glucocorticoids (given by systemic and local routes), beta-2-agonists, and diuretics have intrinsic hyperglycaemic activity.
glukokortikoider (hydrokortison, dexamethason),
glucocorticoids (hydrocortisone, dexamethasone);
Glukokortikoider (indgivet systemisk og lokalt), beta-2-agonister og diuretika har intern hyperglykæmisk aktivitet.
Glucocorticoids (given by systemic and local routes) beta-2-agonists, and diuretics have intrinsic hyperglycaemic activity.
Glukokortikoider (såsom "cortison" til behandling af inflammation (vævsirritation))
Glucocorticoids (such as ‘cortisone’ used to treat inflammation)
Glukokortikoider (såsom `cortison´ til behandling af inflammation (vævsirritation))
Glucocorticoids (such as ‘cortisone’ used to treat inflammation)
Glukokortikoider (såsom `cortison´ til behandling af inflammation)
Glucocorticoids (such as ‘cortisone’ used to treat inflammation)
Glukokortikoider (såsom `cortison´ til behandling af inflammation/betændelsestilstande)
Glucocorticoids (such as ‘cortisone’ used to treat inflammation)
Glukokortikoider (såsom ‘cortison’ til behandling af inflammation/betændelsestilstande)
Glucocorticoids (such as ‘cortisone’ used to treat inflammation)
Glukokortikoider (såsom ’cortison’ til behandling af inflammation (vævsirritation))
Glucocorticoids (such as ‘cortisone’ used to treat inflammation)
Glukokortikoider (såsom ’cortison’ til behandling af inflammation)
Glucocorticoids (such as ‘cortisone’ used to treat inflammation)
Glukokortikoider (såsom ”cortison” til behandling af inflammation (vævsirritation))
Glucocorticoids (such as ‘cortisone’ used to treat inflammation)
glukokortikoider (til behandling af allergier og inflammation)
glucocorticoids (to treat allergies and inflammation)
glukokortikoider (til behandling af allergier og inflammation)
glucocorticoids (used to treat inflammation)
GLUKOKORTIKOIDER (TIL INHALATION)
GLUCOCORTICOIDS (INHALED)
Glukokortikoider (til systemisk og lokal anvendelse), beta-2-agonister og diuretika har en selvstændig hyperglykæmisk virkning.
Glucocorticoids (given by systemic and local routes), beta-2-agonists, and diuretics have intrinsic hyperglycaemic activity.
glukokortikoider ikke, medmindre de
these glucocorticoids is not
glukokortikoider kan det
Pentamidine
Glukose, væske (81,5 % faststof) Sprøjtetørret svineleverpulver Frysetørret vegetabilsk protein Gelatine type A
Glucose, liquid (81.5% solids) Spray dried pork liver powder Hydrolysed vegetable protein Gelatin type A
Glukose- infusions hastighed
Glucose Infusion Rate (mg/min)
Glukosuri
levels2,5
glukosuri
oedema5
Glukosuri Øget appetit
Elevated triglyceride levels2,5 Glucosuria Increased appetite
Glukosuria hos ikke-diabetiske patienter og lave serumkoncentrationer af kalcium, fosfat, magnesium eller urat, fosfaturi, aminoaciduri (monitoreres efter behov)
Glycosuria in non-diabetics and low levels of serum potassium, phosphate, magnesium or urate, phosphaturia, aminoaciduria (monitor as needed).
Glukuronideringssygdom, såsom Gilberts syndrom
Glucuronidation disorder like Gilbert’s syndrome
Glukuronidmetaboliter  
Glucuronide metabolites  
GLULISINE - før
GLULISINE - pre
GLULISINE - før REGULAR - før
80 GLULISINE - post REGULAR - pre
Glustin 15 mg tabletter er hvide til grålighvide, runde, konvekse tabletter, der er mærkede med 15 på den ene side og AD4 på den anden side.
Glustin 15 mg tablets are white to off-white, round, convex tablets marked “15” on one face, “AD4” on the other.
Glustin 15 mg tabletter Glustin 30 mg tabletter Glustin 45 mg tabletter
Glustin 15 mg tablets Glustin 30 mg tablets Glustin 45 mg tablets
Glustin 15 mg tabletter Glustin 30 mg tabletter Glustin 45 mg tabletter Pioglitazon
Glustin 15 mg Tablets Glustin 30 mg Tablets Glustin 45 mg Tablets Pioglitazone
Glustin 15 mg tabletter Pioglitazon
Glustin 15 mg tablets Pioglitazone
Glustin 30 mg tabletter er hvide til grålighvide, runde, flade tabletter, der er mærkede med 30 på den ene side og AD4 på den anden side.
Glustin 30 mg tablets are white to off-white, round, flat tablets marked “30” on one face, “AD4” on the other.
Glustin 30 mg tabletter Pioglitazon
Glustin 30 mg tablets Pioglitazone
Glustin 45 mg tabletter er hvide til grålighvide, runde, flade tabletter, der er mærkede med 45 på den ene side og AD4 på den anden side.
Glustin 45 mg tablets are white to off-white, round, flat tablets marked “45” on one face, “AD4” on the other.
Glustin 45 mg tabletter Pioglitazon
Glustin 45 mg tablets Pioglitazone
Glustin anbefales ikke til børn og unge under 18 år.
Use in children and adolescents under 18 years is not recommended.
Glustin anvendt alene viste sig at være lige så effektivt som metformin og gliclazid.
Glustin on its own was shown to be as effective as metformin and gliclazide.
Glustin førte til et fald i mængden af HbA1c, hvilket viser, at blodglukoseniveauerne var blevet reduceret ved doser a 15, 30 og 45 mg.
Glustin led to a decrease in the level of HbA1c, indicating that blood glucose levels had been reduced at doses of 15, 30 and 45 mg.
Glustin indeholder lactosemonohydrat
Glustin contains lactose monohydrate
Glustin-tabletter indeholder lactosemonohydrat og bør derfor ikke anvendes til patienter med arvelig fructoseintolerans, galactoseintolerans, en særlig form af arvelig lactasemangel (Lapp lactase deficiency) eller glucose/galactosemalabsorption.
Glustin tablets contain lactose monohydrate and therefore should not be administered to patients with rare hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucose-galactose malabsorption.
Glutalmuskulaturen bør ikke benyttes rutinemæssigt som injektionssted på grund af risiko for skade på iskiasnerven.
The gluteal muscle should not be used routinely as an injection site because of the risk of damage to the sciatic nerve.
glutamyl-
glutamyltransferase
Glutealmusklen
gluteal
Glybera anvendes til behandling af voksne patienter, der har fået konstateret arvelig lipoproteinlipase- mangel, (LPLD) og som lider af svære eller gentagne anfald af betændelse i bugspytkirtlen trods fedtfattig diæt.
Glybera is used to treat adult patients diagnosed with lipoprotein lipase deficiency (LPLD) and suffering from severe or multiple pancreatitis attacks despite dietary fat restrictions.
Glybera er et genterapiprodukt.
Glybera is a gene therapy product.
Glybera er et lægemiddel til avanceret terapi, som kaldes et "genterapiprodukt".
Glybera is a type of advanced therapy medicine called a ‘gene therapy product’.
Glybera er godkendt under "særlige omstændigheder" da det som følge af sygdommens sjældenhed ikke har været muligt at undersøge lægemidlet fuldstændigt.
Glybera has been authorised under ‘exceptional circumstances’ as it has not been possible to obtain complete information about the medicine, because of the rarity of the disease.
Glybera indeholder den humane LPL-genvariant LPL S447X i en adeno-associeret virus serotype 1- vektor (AAV1), specifikt målrettet mod muskelvæv.
Glybera contains the human LPL gene variant LPL S447X in an adeno-associated virus serotype 1 (AAV1) vector intended to target the muscle.
Glybera injiceres direkte ind i målorganet, skeletmuskelvæv.
Glybera is injected directly into the target organ, skeletal muscle.
Glybera må ikke anvendes efter den udløbsdato, der står på pakningen efter EXP.
Do not use this medicine after the expiry date which is stated on the label after ‘EXP’.
Glybera må kun gives som én enkelt behandling.
Glybera should be administered to you in one treatment session only.
Glybera Patientkort
Glybera
Glybera. injektionsvæske, opløsning, 3 × 1012 genomkopier/ml
Glybera 3 x 1012 genome copies /ml solution for injection
Glyberas sikkerhed og virkning hos børn og unge under 18 år er ikke undersøgt.
The safety and efficacy of Glybera in children and adolescents below 18 years has not been established.
Glycerol (E 422)
Glycerol (E422) Maltitol liquid (E965)
Glycerol (E422) Carmellosenatrium
Glycerol (E422) Carmellose sodium
Glycerol (E422) Propylenglycol (E1520)
Glycerol (E422) Propylene glycol (E1520)
Glycerol 85% Saccharose
Glycerol 85% Sucrose
Glycerol dibehenat
Glycerol dibehenate
Glycerol Metacresol Phenol Zinkacetat
Glycerol Metacresol Phenol
Glycerol Phenol Metacresol Zinkacetat
Glycerol Phenol Metacresol Zinc acetate